| Purpose | BGI SENTIS Leukemia Gene Detection (DNA+RNA): Leukemia Gene Detection Panel (DNA+RNA) enables the concurrent analysis of both DNA and RNA from blood or bone marrow samples in a single assay to study 373 leukemia related genes associated with hematological malignancies. The panel covers the relevant targets including gene mutations in coding region, 1000+ fusion types and four types of variations for following major myeloid and lymphoid disorders: - Acute Myeloid Leukemia (AML)
- Acute Lymphoblastic Leukemia (ALL)
- Chronic Lymphocytic Leukemia (CLL)
- Chronic Myeloid Leukemia (CML)
SUITABLE FOR: Gene List (183 Genes associated with hematological malignancies Germline Genes (52 Genes): Chemotherapy Related Genes (31Genes): |
| Test Code | BGI SENTIS Leukemia Gene Detection (DNA+RNA) |
| Turnaround Time (TAT) | 20 Days |
| Sample Tested | BGI SENTIS Leukemia Gene Detection (DNA+RNA)- Peripheral blood ≥5mL OR Saliva ≥ 2mL OR ≥ 2-3mL Bone Marrow
|
| Methodology | - DNA Extraction and QC.
- Targeted Capture of 373 leukemia related genes associated with hematological malignancies.
- Highly sensitive detection of actionable mutations from Blood or Bone Marrow samples in 373 leukemia related genes associated with hematological malignancies.
- Reports having information for targeted drugs (Precision Medicine).
- Genetic Counselling.
|
| Advantages | BGI SENTIS Leukemia Gene Detection (DNA+RNA)- All exons plus flanking intronic regions covered for all genes tested (373 leukemia related genes associated with hematological malignancies); one single assay that detects all above mentioned gene mutations in coding region, 1000+ fusion types and four types of variations for following major myeloid and lymphoid disorders:
- A streamlined sample-to-results workflow with MGI’s platform and automated on-premises NGS bioinformatics system, enabling effortless obtainment of insightful reports from samples.
- Providing molecular evidence for the consideration of targeted therapies (Precision Medicine).
|
